Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg nudges up target price on Chesnara

(Sharecast News) - Analysts at Berenberg nudged up their target price on UK life and pension consolidator Chesnara from 328p to 333p on Friday following the group's first-half earnings a day earlier. Chesnara reported £37m H1 cash generation on Thursday, 26% up on H124, a 207% Solvency II ratio, up 203% at its FY24 year-end position, and raised its interim dividend by 3% to 7.7p per share, in line with its annual 3% 20-year DPS growth track record. In addition, Chesnara also updated its guidance for solvency and leverage proforma for the impact of the HSBC Life UK £260m acquisition and for the related financing.

Berenberg, which has a 'buy' rating on the stock, said its new proforma estimates were that Chesnara's leverage ratio would be 25%, down previous guidance of 29%, which excluded the £150m RT1, and that the group's solvency ratio would be 198%.

The German bank updated its forecasts to include the impact of the HSBC Life UK deal and the related financing, stating HSBC Life UK will add over £800m to Chesnara's total cash generation, of which £140m will come in the first five years.

"We estimate that this means that there will clearly be enough cash generation to fund Chesnara's 3% annual DPS growth that we estimate for the next 20 years," said the analysts.

Berenberg added that Chesnara offers an 8.4% FY26 calendar year yield growing at 3% per annum.

"We value Chesnara conservatively on a dividend discount model at 333p per share, and the HSBC UK Life £800m cumulative cash provides comfort that the 3% pa growth is sustainable." it said.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.